242 related articles for article (PubMed ID: 30286330)
1. Iron overload in myelodysplastic syndromes: Evidence based guidelines from the Canadian consortium on MDS.
Leitch HA; Buckstein R; Zhu N; Nevill TJ; Yee KWL; Leber B; Keating MM; St Hilaire E; Kumar R; Delage R; Geddes M; Storring JM; Shamy A; Elemary M; Wells RA
Leuk Res; 2018 Nov; 74():21-41. PubMed ID: 30286330
[TBL] [Abstract][Full Text] [Related]
2. Iron overload in myelodysplastic syndromes: a Canadian consensus guideline.
Wells RA; Leber B; Buckstein R; Lipton JH; Hasegawa W; Grewal K; Yee K; Olney HJ; Larratt L; Vickars L; Tinmouth A
Leuk Res; 2008 Sep; 32(9):1338-53. PubMed ID: 18405971
[TBL] [Abstract][Full Text] [Related]
3. Decision points in the treatment of transfusional iron overload in patients with myelodysplastic syndromes: why, when, and how to chelate.
Imran F; Phatak P
Expert Rev Hematol; 2017 Jan; 10(1):53-64. PubMed ID: 27923273
[TBL] [Abstract][Full Text] [Related]
4. Optimizing therapy for iron overload in the myelodysplastic syndromes: recent developments.
Leitch HA
Drugs; 2011 Jan; 71(2):155-77. PubMed ID: 21275444
[TBL] [Abstract][Full Text] [Related]
5. Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload.
Gattermann N
Int J Hematol; 2008 Jul; 88(1):24-29. PubMed ID: 18581200
[TBL] [Abstract][Full Text] [Related]
6. Diagnosis, management and response criteria of iron overload in myelodysplastic syndromes (MDS): updated recommendations of the Austrian MDS platform.
Valent P; Stauder R; Theurl I; Geissler K; Sliwa T; Sperr WR; Bettelheim P; Sill H; Pfeilstöcker M
Expert Rev Hematol; 2018 Feb; 11(2):109-116. PubMed ID: 29292655
[TBL] [Abstract][Full Text] [Related]
7. NCCN Task Force: Transfusion and iron overload in patients with myelodysplastic syndromes.
Greenberg PL; Rigsby CK; Stone RM; Deeg HJ; Gore SD; Millenson MM; Nimer SD; O'Donnell MR; Shami PJ; Kumar R
J Natl Compr Canc Netw; 2009 Dec; 7 Suppl 9():S1-16. PubMed ID: 20064286
[TBL] [Abstract][Full Text] [Related]
8. Iron overload in myelodysplastic syndromes: diagnosis and management.
List AF
Cancer Control; 2010 Jan; 17 Suppl():2-8. PubMed ID: 20125080
[TBL] [Abstract][Full Text] [Related]
9. Guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload.
Gattermann N
Leuk Res; 2007 Dec; 31 Suppl 3():S10-5. PubMed ID: 18037413
[TBL] [Abstract][Full Text] [Related]
10. Intracellular ROS profile in hematopoietic progenitors of MDS patients: association with blast count and iron overload.
Chan LSA; Gu LC; Leitch HA; Wells RA
Hematology; 2021 Dec; 26(1):88-95. PubMed ID: 34000978
[No Abstract] [Full Text] [Related]
11. Iron overload in myelodysplastic syndromes (MDS).
Gattermann N
Int J Hematol; 2018 Jan; 107(1):55-63. PubMed ID: 29177643
[TBL] [Abstract][Full Text] [Related]
12. Iron overload impairs normal hematopoietic stem and progenitor cells through reactive oxygen species and shortens survival in myelodysplastic syndrome mice.
Jin X; He X; Cao X; Xu P; Xing Y; Sui S; Wang L; Meng J; Lu W; Cui R; Ni H; Zhao M
Haematologica; 2018 Oct; 103(10):1627-1634. PubMed ID: 29903757
[TBL] [Abstract][Full Text] [Related]
13. Supportive care and chelation therapy in MDS: are we saving lives or just lowering iron?
Leitch HA; Vickars LM
Hematology Am Soc Hematol Educ Program; 2009; ():664-72. PubMed ID: 20008252
[TBL] [Abstract][Full Text] [Related]
14. To chelate or not to chelate in MDS: That is the question!
Zeidan AM; Griffiths EA
Blood Rev; 2018 Sep; 32(5):368-377. PubMed ID: 29602612
[TBL] [Abstract][Full Text] [Related]
15. Iron overload in myelodysplastic syndromes (MDS) - diagnosis, management, and response criteria: a proposal of the Austrian MDS platform.
Valent P; Krieger O; Stauder R; Wimazal F; Nösslinger T; Sperr WR; Sill H; Bettelheim P; Pfeilstöcker M
Eur J Clin Invest; 2008 Mar; 38(3):143-9. PubMed ID: 18218040
[TBL] [Abstract][Full Text] [Related]
16. Myelodysplastic syndromes and the role of iron overload.
Harvey RD
Am J Health Syst Pharm; 2010 Apr; 67(7 Suppl 2):S3-9. PubMed ID: 20332503
[TBL] [Abstract][Full Text] [Related]
17. Iron overload in patients with myelodysplastic syndromes: An updated overview.
Moukalled NM; El Rassi FA; Temraz SN; Taher AT
Cancer; 2018 Oct; 124(20):3979-3989. PubMed ID: 29905937
[TBL] [Abstract][Full Text] [Related]
18. Controversies surrounding iron chelation therapy for MDS.
Leitch HA
Blood Rev; 2011 Jan; 25(1):17-31. PubMed ID: 21030120
[TBL] [Abstract][Full Text] [Related]
19. Iron overload and chelation therapy in myelodysplastic syndromes.
Temraz S; Santini V; Musallam K; Taher A
Crit Rev Oncol Hematol; 2014 Jul; 91(1):64-73. PubMed ID: 24529413
[TBL] [Abstract][Full Text] [Related]
20. Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology.
Alessandrino EP; Amadori S; Barosi G; Cazzola M; Grossi A; Liberato LN; Locatelli F; Marchetti M; Morra E; Rebulla P; Visani G; Tura S;
Haematologica; 2002 Dec; 87(12):1286-306. PubMed ID: 12495903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
